Brokerages Set Candel Therapeutics, Inc. (NASDAQ:CADL) Target Price at $18.50

Candel Therapeutics (NASDAQ:CADL) maintains an average analyst rating of "Moderate Buy" with a consensus 12-month price target of $18.33, despite recent mixed analyst actions including an upgrade by Stephens and a downgrade by Bank of America. The clinical-stage biopharmaceutical company, which develops cancer immunotherapies like CAN-2409 in various clinical trial phases, recently reported a Q3 EPS of ($0.21), missing the consensus estimate of ($0.17). Trading around $4.64, the stock is significantly below its average price target, indicating a nuanced market perspective on its pipeline and recent financial performance.

Analysis

Candel Therapeutics (NASDAQ:CADL) maintains an average "Moderate Buy" rating from eight analysts, with a consensus 12-month price target of $18.33. This target implies substantial upside from the current trading price of $4.64, which saw a 0.7% increase on Thursday's open. The analyst sentiment is predominantly positive, with four "Buy" and two "Strong Buy" ratings, tempered by one "Hold" and one "Sell" recommendation.

Recent analyst actions have been bifurcated, featuring an upgrade to "strong-buy" by Stephens and new "outperform" coverage from Lifesci Capital, contrasted by Bank of America's downgrade to "neutral" and a price target cut from $13 to $7. The company reported a Q3 EPS of ($0.21), missing the consensus estimate of ($0.17), with full-year EPS forecast at -1.47. Despite unprofitability, CADL demonstrates robust liquidity with a quick ratio and current ratio of 7.04 and a very low debt-to-equity ratio of 0.01.

As a clinical-stage biopharmaceutical firm, Candel Therapeutics' valuation is intrinsically linked to its immunotherapy pipeline, particularly CAN-2409, which is in Phase II/III trials for various cancers. The stock's current trading level of $4.64 is below its 50-day ($5.32) and 200-day ($5.54) simple moving averages, and significantly off its 52-week high of $14.60. The negative P/E ratio of -8.14 is characteristic of pre-revenue or early-stage biotech companies.

Key Decisions for Investors

• Investors should weigh the significant implied upside from the consensus price target against the recent Q3 EPS miss and mixed analyst sentiment.
• Close monitoring of the progress and clinical trial results for Candel Therapeutics' lead immunotherapy candidate, CAN-2409, is crucial, as pipeline advancements will be key catalysts.
• Consider the company's strong balance sheet, characterized by high liquidity and minimal debt, as a supportive factor for its long-term R&D efforts despite current unprofitability.